BNTX - Pfizer's Doldrums Just A Bad Case Of COVID-19?

2024-04-16 09:15:50 ET

Summary

• PFE's dividend has reached the sky-high (for a biotech) ~6% mark.
• Are the dividend and recent share price decline enough to make PFE an attractive play?
• PFE is following a similar trajectory to GILD in its post-HCV stagnation.
• PFE may be worth buying as the COVID-based product revenues decline and equilibrate.

Introduction:

A biotech stock with a large dividend is pretty uncommon since biotechnology and pharmaceutical companies tend to focus more on reinvestment into pipeline growth rather than shareholder returns. But as a biopharma grows larger and there may be a paucity of potential pipeline or partnership opportunities that may be worth investing in, the company may look to return some of its profits to its investors through either dividends or share repurchases. Pfizer ( PFE ) seems to be one of these companies, where the combination of recent share price declines and a steadily growing dividend had caused the company's yield to eclipse the 6% level....

For further details see: